A clinical study to investigate the safety, tolerability, immunogenicity and efficacy of HTI T-cell vaccine and vesatolimod in HIV-infected individuals on antiretroviral therapy.
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
At a glance
- Drugs HTI immunogen (Primary) ; Vesatolimod (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms AELIX-003
- 26 Oct 2018 New trial record
- 18 Oct 2018 According to an Aelix Therapeutics media release, the initiation of AELIX-003 is targeted for early 2019.